American Chemical Society
jm6b00237_si_004.pdb (3.75 MB)

Design, Synthesis, and Preclinical Evaluation of 4‑Substituted-5-methyl-furo[2,3‑d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells

Download (3.75 MB)
posted on 2016-05-23, 00:00 authored by Ravi Kumar Vyas Devambatla, Ojas A. Namjoshi, Shruti Choudhary, Ernest Hamel, Corena V. Shaffer, Cristina C. Rohena, Susan L. Mooberry, Aleem Gangjee
The design, synthesis, and biological evaluations of eight 4-substituted 5-methyl-furo­[2,3-d]­pyrimidines are reported. Synthesis involved N4-alkylation of N-aryl-5-methylfuro­[2,3-d]­pyrimidin-4-amines, obtained from Ullmann coupling of 4-amino-5-methylfuro­[2,3-d]­pyrimidine and appropriate aryl iodides. Compounds 3, 4, and 9 showed potent microtubule depolymerizing activities, while compounds 68 had slightly lower potency. Compounds 4, 6, 7, and 9 inhibited tubulin assembly with IC50 values comparable to that of combretastatin A-4 (CA-4). Compounds 3, 4, and 69 circumvented Pgp and βIII-tubulin mediated drug resistance, mechanisms that can limit the efficacy of paclitaxel, docetaxel, and the vinca alkaloids. In the NCI 60-cell line panel, compound 3 exhibited GI50 values less than 10 nM in 47 of the cell lines. In an MDA-MB-435 xenograft model, compound 3 had statistically significant antitumor effects. The biological effects of 3 identify it as a novel, potent microtubule depolymerizing agent with antitumor activity.